Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

Patients must have histologically confirmed malignancy that is metastatic or unresectable

Cancers with positive BRAF V600 mutation detected by a Clinical Laboratory Improvement Act (CLIA)-certified laboratory

Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

Life expectancy of greater than 3 months

Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria

Patients must have a K-RAS wild-type (WT) tumor

Absolute neutrophils count \>= 1500/mcl (within 14 days)

Platelets \>= 100000/mcl (within 14 days)

Hemoglobin (Hb) \>= 9 mg/dl (within 14 days)

Total bilirubin =\< 1.5 mg/dl (within 14 days)

Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 5 x upper limit of normal if liver metastases present; otherwise, then =\< 2.5 x upper limit (within 14 days)

Estimated creatinine clearance by Cockcroft-Gault equation \> 30 mL/min (within 14 days)

Current treatment may cause harm to the developing human fetus; for this reason women of child-bearing age must have a negative pregnancy test at screening and both women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation, and for 6 months after last dose; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately

Signed informed consent approved by the Institutional Review Board prior to patient entry

Expansion cohort: We propose a final expansion cohort for this study in a subset of interest utilizing the recommended dosing of combination; this cohort will include patients harboring characteristics that may predict response of combination or with clinical features that proved to derive most benefit of the study combination during preclinical studies; cancers with positive BRAF (V600) mutation detected by a CLIA-certified laboratory

What this study is about